Overcoming Drug Resistance: The EGFR Enigma

EGFR square

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More

Stepping Into the Era of Combination Cancer Therapies, Part 2: Combining Targeted Therapies

"Philadelphia, PA - The AACR 2015 Annual Meeting - Ursala Matulonis discusses her research during the AACR Press Conference at the American Association for Cancer Research Annual Meeting here today, Tuesday April 21, 2015. More than 18,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the meeting at the Pennsylvania Convention Center. The Annual Meeting highlights the latest findings in all major areas of cancer research from basic through clinical and epidemiological studies. Photo by © AACR/Todd Buchanan 2015 Contact Info: todd@medmeetingimages.com Keywords: 15AACR_Meet the Editors: Cancer Discovery session"

In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015 that hold promise for combination cancer therapies, I discussed clinical trials …

Read More

An Ounce of Prevention: Researching New Ways to Circumvent the Development of Gastric Cancer


Tamas A. Gonda, MD, 2014 recipient of the Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research, is examining how epigenetic changes can be targeted to prevent gastric cancer.

Read More

Stepping Into the Era of Combination Cancer Therapies, Part 1: Combining Immunotherapies


Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The outcomes with immunotherapies, in particular, are so compelling that cancer clinicians …

Read More

New Immunotherapy Advances Presented at the AACR Annual Meeting 2015

AACR Press Conference

Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals …

Read More